Frequency of Medication Use among Liver Transplant Candidates and Recipients during the COVID-۱۹ Pandemic

سال انتشار: 1403
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 189

فایل این مقاله در 5 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_JSTR-12-2_005

تاریخ نمایه سازی: 12 آذر 1403

چکیده مقاله:

Introduction: The liver is recognized as a primary target in COVID-۱۹ due to its susceptibility to viral infection and its prominent role in the body’s immune and metabolic responses. The present study aims to investigate the frequency of supplement and medication use among liver transplant recipients and candidates during the COVID-۱۹ pandemic. Methods: This cross-sectional study included demographic and clinical information from ۱۷۰ liver transplant recipients and candidates who had sought care at the Guilan Transplant Center in Rasht, Iran. The participants' history of taking supplements, antibiotics, immunosuppressants, antiviral and gastrointestinal medications, and their COVID-۱۹ infection history were recorded. Statistical analysis of the data was performed using SPSS software (version ۲۲). Results: Of the total ۱۷۰ individuals in the study, ۸۴(۴۹.۴%) were candidates for liver transplants, while ۸۶(۵۱.۶%) had already received liver transplants. Among liver transplant candidates, ۲(۲.۴%) were infected with COVID-۱۹, and one died; among the liver transplant recipients, ۸(۹.۳%) patients had COVID-۱۹, and three died. Among liver transplant recipients, the most frequently consumed supplements, immunosuppressive, antibiotics, antiviral, and gastrointestinal medications were Vitamin D (۷۷.۹%), Prednisolone (۹۰.۱%), Cotrimoxazole (۵.۸%), Tenofovir (۱۶.۸%), and Pantoprazole (۷۴.۴%), respectively. Among liver transplants, the candidates were folic acid (۳۲.۱%), Prednisolone (۲۰.۲%), Azithromycin (۱.۲%), Tenofovir (۵.۹%), and Pantoprazole (۵۱.۲%). Conclusion: Individuals who have received liver transplants and have a history of medication use are more susceptible to contracting COVID-۱۹. The findings underscored the vulnerability of transplant recipients, particularly those on long-term immunosuppressive therapy, to SARS-CoV-۲ infection. The prevalence of underlying diseases in both groups further emphasized the need for heightened vigilance and tailored preventive measures.

نویسندگان

Seyyed Ali Alavi Foumani

Inflammatory Lung Diseases Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

Pirouz Samidoust

Inflammatory Lung Diseases Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

Tofigh Yaghoubi

Inflammatory Lung Diseases Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

Kourosh Delpasand

Inflammatory Lung Diseases Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

Seyyed Sina Mesbah

Inflammatory Lung Diseases Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Halaji M, Heiat M, Faraji N, Ranjbar R. Epidemiology of ...
  • Zeinali T, Faraji N, Joukar F, Maroufizadeh S, Shenagari M, ...
  • Faraji N, Zeinali T, Joukar F, Aleali MS, Eslami N, ...
  • Zeinali T, Faraji N, Joukar F, Khan Mirzaei M, Kafshdar ...
  • Yaghubi T, Shakoori V, Nasiri S, Keivan M, Tavakol C, ...
  • Haghighi M, Khoshrang H, Rimaz S, Kalurazi TY, Atrkar Z, ...
  • Kalurazi TY, Shakoori V, Nasiri S, Foumani AA, Hesni E, ...
  • Banerjee D, Popoola J, Shah S, Ster IC, Quan V, ...
  • Sahin TT, Akbulut S, Yilmaz S. COVID-۱۹ pandemic: Its impact ...
  • Zingone F, Savarino EV. Viral screening before initiation of biologics ...
  • Belli LS, Duvoux C, Karam V, Adam R, Cuervas-Mons V, ...
  • Hamulka J, Jeruszka-Bielak M, Górnicka M, Drywień ME, Zielinska-Pukos MA. ...
  • Hashemi R, Montazer M, Salehi Z, Azadbakht L. Association of ...
  • Alqahtani SA, Schattenberg JM. Liver injury in COVID-۱۹: The current ...
  • Mulder MB, Borgsteede SD, Darwish Murad S, Landman CS, Metselaar ...
  • El Kassas M, Alboraie M, Al Balakosy A, Abdeen N, ...
  • Kulkarni A V, Tevethia HV, Premkumar M, Arab JP, Candia ...
  • Lau G, Sharma M. Clinical practice guidance for hepatology and ...
  • Lavrinenko A, Kolesnichenko S, Kadyrova I, Turmukhambetova A, Akhmaltdinova L, ...
  • Karami Z, Knoop BT, Dofferhoff ASM, Blaauw MJT, Janssen NA, ...
  • Eggersdorfer M, Berger MM, Calder PC, Gombart AF, Ho E, ...
  • Demelash S, Takele T, Zeynu N, Temesgen S, Ayano G. ...
  • نمایش کامل مراجع